Non‐hemodynamic effects:Repurposing of nonselective beta‐blockers in cirrhosis?  

作　　者：Yi Yang Mingkai Li Jinni Luo Hongsheng Yu Hong Tian Xing Wang 

机构地区：[1]Department of Gastroenterology,The Third Affiliated Hospital of Sun Yat‐sen University,Guangzhou,China [2]School of Medicine,Xizang Minzu University,Xianyang,China [3]Guangdong Provincial Key Laboratory of Liver Disease Research,Guangzhou,China

出　　处：《Portal Hypertension & Cirrhosis》2022年第2期153-156,共4页门静脉高压与肝硬化（英文）

基　　金：supported by grants from the National Natural Science Foundation of China(No.82070574).

摘　　要：To the Editor:Liver cirrhosis(LC),the end‐stage condition of chronic liver disease,results in>1,300,000 annual deaths worldwide.Meanwhile,the global incidence of decompensated cirrhosis is rising yearly.1 Following clinically significant portal hypertension(CSPH)in the late compensated stage of LC,as the disease progresses to the decompensated stage,ascites,gastroesophageal variceal bleeding,hepatic encephalopathy(HE),and other severe complications present.Nonselective beta‐blockers(NSBBs)have currently served as the first‐line therapy for primary and secondary prophylaxis of portal‐hypertensive gastrointestinal bleeding,as recommended by practice guidelines.2 Moreover,recent recommendations have extended the use of NSBBs to compensate LC patients with CSPH.

关 键 词：CIRRHOSIS BLEEDING HYPERTENSIVE 

分 类 号：R57[医药卫生—消化系统]